Axial spondyloarthritis - Pipeline Insight, 2021

May 2021
80 pages
ID: 5028112
Format: PDF
Delve Insight

Summary

Table of Contents

“Axial spondyloarthritis - Pipeline Insight, 2021,” report provides comprehensive insights about 30+ companies and 30+ pipeline drugs in Axial spondyloarthritis pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered
• Global coverage

Axial spondyloarthritis Understanding

Axial spondyloarthritis: Overview
The term axial spondyloarthritis covers both the early inflammatory phase of the disease in which there is no structural damage in the sacroiliac joints (non-radiographic disease) and the later stages in which structural damage is visible on X?ray scans of the sacroiliac joints as erosions, sclerosis or bony bridges (radiographic disease; also known as ankylosing spondylitis). In addition, patients with radiographic axial spondyloarthritis might have abnormalities in X?ray scans of the spine, the most important one being syndesmophytes (vertical bony growth between the corners of two vertebral bodies).
Axial spondyloarthritis is divided into non-radiographic and radiographic disease (also known as ankylosing spondylitis) according to the presence of radiographic changes of the sacroiliac joints. Changes in the spine evident on X-ray can occur in radiographic axial spondyloarthritis, but spinal radiographs can also be normal.

"Axial spondyloarthritis - Pipeline Insight, 2021" report outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Axial spondyloarthritis pipeline landscape is provided which includes the disease overview and Axial spondyloarthritis treatment guidelines. The assessment part of the report embraces, in depth Axial spondyloarthritis commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Axial spondyloarthritis collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights
• The companies and academics are working to assess challenges and seek opportunities that could influence Axial spondyloarthritis R&D.; The therapies under development are focused on novel approaches to treat/improve Axial spondyloarthritis.

Axial spondyloarthritis Emerging Drugs Chapters
This segment of the Axial spondyloarthritis report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Axial spondyloarthritis Emerging Drugs
• Tofacitinib: Pfizer
Tofacitinib, sold under the brand Xeljanz among others, is a medication used to treat rheumatoid arthritis, psoriatic arthritis, and ulcerative colitis. Tofacitinib is an inhibitor of Janus kinases, a group of intracellular enzymes involved in signalling pathways that affect hematopoiesis and immune cell function. By inhibiting JAKs, tofacitinib prevents the phosphorylation and activation of STATs.

• Bimekizumab: UCB Biopharma
Bimekizumab is an investigational humanized monoclonal IgG1 antibody that selectively inhibits both IL-17A and IL-17F. Bimekizumab binds to and neutralizes IL-17A and IL-17F, preventing their interactions with the IL-17 receptors expressed on keratinocytes, fibroblast-like synoviocytes, endothelial cells, chondrocytes and osteoblasts. The drug is currently in phase 3 of development stage for the treatment of Axial spondylarthritis.

• Tildrakizumab: Sun Pharma Global
Tildrakizumab is a humanized IgG1/k monoclonal antibody that selectively binds to the p19 subunit of the interleukin-23 (IL-23) cytokine and inhibits its interaction with the IL-23 receptor. IL-23 plays a critical role in modulating inflammatory and immune responses. In March 2018, the biological treatment tildrakizumab (Ilumya) received US Food and Drug Administration (FDA) approval for the treatment of moderate-to-severe plaque psoriasis in patients who are candidates for systemic therapy or phototherapy.
Further product details are provided in the report……..

Axial spondyloarthritis: Therapeutic Assessment
This segment of the report provides insights about the different Axial spondyloarthritis drugs segregated based on following parameters that define the scope of the report, such as:
• Major Players in Axial spondyloarthritis
There are approx. 30+ key companies which are developing the therapies for Axial spondyloarthritis. The companies which have their Axial spondyloarthritis drug candidates in the most advanced stage, i.e. phase III include, UCB Biopharma.

• Phases
This report covers around 30+ products under different phases of clinical development like
• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

• Route of Administration
Axial spondyloarthritis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
• Oral
• Intravenous
• Subcutaneous
• Topical.
• Molecule Type

Products have been categorized under various Molecule types such as
• Monoclonal Antibody
• Oligonucleotide
• Recombinant fusion proteins
• Small molecule
• Peptide vaccine
• Product Type
Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Axial spondyloarthritis: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Axial spondyloarthritis therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Axial spondyloarthritis drugs.

Axial spondyloarthritis Report Insights
• Axial spondyloarthritis Pipeline Analysis

• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Axial spondyloarthritis Report Assessment
• Pipeline Product Profiles

• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:
• How many companies are developing Axial spondyloarthritis drugs?
• How many Axial spondyloarthritis drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Axial spondyloarthritis?
• What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Axial spondyloarthritis therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Axial spondyloarthritis and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players
• Pfizer
• Mycenax Biotech
• Clover Biopharmaceuticals
• Celltrion
• UCB
• Gilead Sciences
• Amgen
• Genrix (Shanghai) Biopharmaceuticals
• Sun Pharma Global
• Boehringer Ingelheim
• Jiangsu HengRui Medicine
• Izana Bioscience
• 3SBio
• Tasly Pharmaceuticals Inc.
• Suzhou Zelgen Biopharmaceuticals
• Affibody
• Kinevant Sciences
• Qyuns Therapeutics
• Akeso Biopharma
• Jiangsu HengRui Medicine Co., Ltd
• FunPep Co Ltd.
• Luye Pharma Group
• siRNAgen Therapeutics
• Aclaris Therapeutics
• Dice molecules

Key Products
• Tofacitinib
• ENIA11
• SCB-808
• CT-P17
• Bimekizumab
• Filgotinib
• Apremilast
• GR1501
• Tildrakizumab
• BI 730357
• SHR0302
• Namilumab
• SSS07
• Jitongning tablets
• Jaktinib
• ABY-035
• KIN-1901
• QX002N
• AK111
• SHR-1314
• FPP003
• TS8108
• Amphisiran

Our reports have been used by over 10K customers, including:

Get Industry Insights. Simply.

Latest reports & slideshows with insights from top research analysts
150+ Million searchable statistics with tables, figures & datasets
More than 25,000 trusted sources

Single User License — provides access to the report by one individual.
Department License — allows you to share the report with up to 5 users
Site License — allows the report to be shared amongst all employees in a defined country
Corporate License — allows for complete access, globally.

ReportLinker may already be registered as a supplier with your company. If you want to Order by PO, check with us first and we'll let you know if we are a registered supplier and what the vendor number is. Otherwise, we'll provide you with the necessary information to register ReportLinker as a vendor.

Ahmad helps you find the right report:

+1 718 618 4302
Contact by email

Testimonials

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at
Ikea

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at
Ingredion

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

FAQ

How we can help
- I am not sure if the report I am interested in will fulfill my needs. Can you help me?
- Yes, of course. You can call us at +33(0) 4 37 65 17 03 or drop us an email at [email protected] to let us know more about your requirements.
- We buy reports often - can ReportLinker get me any benefits?
- Yes. Set up a call with a Senior Research Advisor to learn more - [email protected] or +33(0) 4 37 65 17 03.
- I have had negative experiences with market research reports before. How can you avoid this from happening again?
- We advise all clients to read the TOC and Summary and list your questions so that we can get more insight for you before you make any purchase decision. A research advisor will accompany you so that you can compare samples and reports from different sources, and choose the study that is right for you.
Report Delivery
- How and when I will receive my Report?
- Most reports are delivered right away in a pdf format, while others are accessed via a secure link and access codes. Do note that sometimes reports are sent within a 12 hour period, depending on the time zones. However, you can contact us to escalate this. Should you need a hard copy, you can check if this option is offered for the particular report, and pay the related fees.
Payment conditions
- What payment methods do you accept?
- 1. Credit card : VISA, American Express, Mastercard, or
  2. You can download an invoice to pay by wire transfer, check, or via a Purchase Order from your company, or
  3. You can pay via a Check made out in US Dollars, Euros, or British Pounds for the full amount made payable to ReportLinker
- What are ReportLinker’s Payment Terms?
- All payments must normally be submitted within 30 days. However, you can let us know if you need extended time.
- Are Taxes and duties included?
- All companies based in France must pay a 20% tax per report. The same applies to all individuals based in the EU. All EU companies must supply their VAT number when purchasing to avoid this charge.
- I’m not satisfied. Can I be refunded?
- No. Once your order has been processed and the publisher has received a notification to send you the report, we cannot issue any refund or cancel any order. As these are not ‘traditional’ products that can be returned, reports that are dispatched are considered to be ‘consumed’.
User license
- The license that you should acquire depends on the number of persons that need to access the report. This can range from Single User (only one person will have the right to read or access the report), or Department License (up to 5 persons), to Site License (a group of persons based in the same company location), or Corporate License (the entire company personnel based worldwide). However, as publishers have different terms and conditions, we can look into this for you.

Purchase Reports From Reputable Market Research Publishers

Neutropenia - Pipeline Insight, 2021

$ 2000
May 2021
60 pages

“Neutropenia - Pipeline Insight, 2021,” report provides comprehensive insights about 20+ companies and 30+ pipeline drugs in Neutropenia pipeline landscape. It covers the pipeline drug profiles, including ...